ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.
IPO Year: 2015
Exchange: NASDAQ
Website: immunitybio.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/12/2023 | $10.00 → $4.00 | Overweight → Neutral | Piper Sandler |
8/3/2022 | $8.00 | Buy | Jefferies |
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
10-Q - ImmunityBio, Inc. (0001326110) (Filer)
8-K - ImmunityBio, Inc. (0001326110) (Filer)
S-8 - ImmunityBio, Inc. (0001326110) (Filer)
8-K - ImmunityBio, Inc. (0001326110) (Filer)
10-Q - ImmunityBio, Inc. (0001326110) (Filer)
EFFECT - ImmunityBio, Inc. (0001326110) (Filer)
DEFA14A - ImmunityBio, Inc. (0001326110) (Filer)
DEF 14A - ImmunityBio, Inc. (0001326110) (Filer)
ARS - ImmunityBio, Inc. (0001326110) (Filer)
8-K - ImmunityBio, Inc. (0001326110) (Filer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line NSCLC cancer patients who progressed on checkpoint inhibitors such as KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab) ANKTIVA plus KEYTRUDA or OPDIVO rescued T cell activity in these patients who progressed on the same checkpoint inhibitor with overall survival of 57% at 12 months Long-term survival was independent of PDL1 tumor status and independent of 2nd or 3rd line of therapy The data continues to validate the mechanism of action of ANKTIVA in activating NK, CD8 killer, and Memory T cells resulting in prolonged overall survival in pati
ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval Global expansion of commercial and clinical bladder cancer programs Filing process initiated with European Medicines Agency (EMA) for regulatory approval of ANKTIVA in European Union countries Global filing for BCG naïve trial initiated (QUILT-2.005) in India ANKTIVA Non-Small Cell Lung Cancer (NSCLC) FDA meeting held in June 2024 ImmunityBio, Inc. ((IBRX), today announced significant progress in market access, making ANKTIVA® (nogapendekin alfa inbakicept-pmln) widely available to patients through both commercial and government insurance programs. The company
The QUILT 502 trial is testing ImmunityBio's N-803 (ANKTIVA®) in combination with the AdHER2DC investigational vaccine for endometrial cancer, a gynecological cancer with lower survival rates and limited effective post-second-line treatment. The AdHER2DC vaccine targets the HER2 protein, which is elevated in 30% of endometrial cancer. ANKTIVA, recently approved for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, is designed to activate the immune cells that kill tumor cells to provide long-term immune response. The Phase1/2 interventional study will enroll 60 participants with HER2-positive endometrial cancer (EC), who will also receive pembrolizumab and len
Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer ANKTIVA launch initiates the next era of immunotherapy beyond checkpoint inhibitors that is based on cytokines and natural killer (NK) cells ANKTIVA's novel mechanism of action activates the body's immune system of natural killer and killer T cells to attack BCG resistant tumor cells and induce memory T cells resulting in a long duration of complete response exceeding 47 months1 ANKTIVA reimbursement now covered by multiple healthcare plans Urologists treating eligible bladder cancer pati
ImmunityBio, Inc. ((IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Officer and President, will provide a business update after the formal business of the Annual Meeting has ended. All interested parties are welcome to attend the Annual Meeting and listen to the Company update. Non-stockholders can attend the vir
Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T cells, and Memory T cells The clinical findings of a durable complete response and implications for nonmuscle invasive bladder cancer patients with the launch of ANKTIVA Addressing the shortage of BCG and collaboration with Serum Institute of India ImmunityBio, Inc. ((IBRX) today announced the publication of three podcasts with UroToday highlighting the company's recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advances in bladder cance
ANKTIVA® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on track to be completed in 12-18 months with capacity to produce a million vials annually Coupled with a recent announcement of BCG availability in partnership with the Serum Institute of India (SII), ImmunityBio has large-scale inventory and capacity for BCG ImmunityBio, Inc. ((IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for "fill finish" (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg A
Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio's recently approved treatment for non-muscle invasive bladder cancer (NMIBC) Serum Institute of India (SII) will manufacture both standard BCG ("sBCG") and next-generation recombinant BCG ("iBCG"), creating a long-term solution to chronic BCG supply shortage issues Standard BCG (sBCG) from the Serum Institute is currently administered in number of countries worldwide for treatment of NMIBC Recombinant BCG (iBCG) has demonstrated potent immunogenicity with CD8+ and CD4+ stimulation and improved safety compared to standard BCG in clinical trials across Europe. Collaborati
USA News Group Commentary Issued on behalf of BioVaxys Technology Corp. VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catal
Dr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program "A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy for NMBIC" Discussion about the basis for ANKTIVA's Breakthrough Therapy designation and the novel mechanism of how the IL-15 superagonist achieves durable complete responses in BCG unresponsive NMIBC The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. ((IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination with bacillus Calmette-Guerin (BCG) for non-muscle invasive bl
Dr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program "A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy for NMBIC" Discussion about the basis for ANKTIVA's Breakthrough Therapy designation and the novel mechanism of how the IL-15 superagonist achieves durable complete responses in BCG unresponsive NMIBC The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. ((IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination with bacillus Calmette-Guerin (BCG) for non-muscle invasive bl
QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types Meeting scheduled with FDA in June to discuss path to registration filing of ANKTIVA plus che
Designated an FDA Breakthrough Therapy, the novel immunotherapy ANKTIVA activates the body's natural killer (NK) and killer T-cell immune system to attack tumor cells Therapy stimulates memory T cells, leading to long duration of complete response exceeding 47 months and ongoing to date, with a median duration of response yet to be determined The percentage of patients with durable responses at 12 and 24 months exceeded the benchmark for magnitude of clinically meaningful results established by experts at the International Bladder Cancer Group (IBCG) ANKTIVA in combination with BCG is approved for maintenance therapy for up to 37 months with tolerable side effects ranging from 0%
EMERYVILLE, Calif., Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced financial results for its third quarter ended September 30, 2021. "Amyris delivered another strong quarter along with solid strategic execution amid challenging external global supply chain conditions," said John Melo, President and Chief Executive Officer. "Once again, we realized record underlying revenue and record consumer revenue demonstrating
ImmunityBio, Inc. ((IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Officer and President, will provide a business update after the formal business of the Annual Meeting has ended. All interested parties are welcome to attend the Annual Meeting and listen to the Company update. Non-stockholders can attend the vir
- Yun Han named Chief Accounting Officer and Interim Chief Financial Officer - - Initial Funding Expected This Week Under $60 Million Financing Agreement - Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") (NASDAQ:FFIE), a California-based global shared intelligent electric mobility ecosystem company, today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. Ms. Han replaces Becky Roof, who served as interim Chief Financial Officer until October 12, 2022, and is assisting the Company to ensure an orderly transition. This press release features multimedia. View the full release here: htt
Biopharma leaders bring proven market development talents in urology and oncology to bolster company's commercialization plan and long-term growth plans Helen Luu, former CEO of Cell BT, is named ImmunityBio's first Chief Commercial Officer and brings a strong background in product commercialization in the urology market, business development, sales growth, and oncology market expansion. Sigrid Schreiner joins as Senior Vice President of Global Market Access, adding decades of market access experience to the leadership team, including the market launch of chemotherapy Abraxane®. ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, today announced two key executive
Dr. Soon-Shiong's priority will be to continue to align scientific and medical goals that are focused on the delivery of cutting-edge therapeutics for patients. The role connects Dr. Soon-Shiong's long-time expertise, track record and innovative thinking as a clinician scientist directly with the company's talented research/discovery, clinical development, and medical teams. The new position is in addition to Dr. Soon-Shiong's existing role as the company's Executive Chairman of the Board. ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, appointed Patrick Soon-Shiong, M.D., to the newly created role of Global Chief Scientific and Medical Officer, effective as
Ambrx (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointment of Sonja Nelson to Chief Financial Officer. "I am delighted to welcome Sonja to Ambrx as we expand our executive team, in light of our ongoing expansion," said Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx. "Sonja brings a breadth of experience in financial operations, planning and strategy from within the biotechnology industry. Her arrival at Ambrx solidifies the company's management team, and I look forward to leaning on her experience as we transition into the next stages of our
FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Company's Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (NASDAQ:NK) an
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the appointment of health innovation expert and executive Linda Maxwell, M.D., MBA, as an independent member of the company’s board of directors. The company also appointed CEO Richard Adcock to the board; he was named CEO of NantKwest in October and remains the CEO of the company after the merger of NantKwest with ImmunityBio in March. Both appointments are effective March 29, 2021. The nine-member ImmunityBio board is led by Founder and Executive Chairman Patrick Soon-Shiong, M.D. The board includes two other recently appointed outside members, former
Piper Sandler downgraded ImmunityBio from Overweight to Neutral and set a new price target of $4.00 from $10.00 previously
Jefferies initiated coverage of ImmunityBio with a rating of Buy and set a new price target of $8.00
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Bilibili Inc. (NASDAQ:BILI) shares rose 23.32% following last week’s release of ‘San Guo: Mou Ding Tian Xia.’ Also, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price forecast. ImmunityBio, Inc. (NASDAQ:IBRX) shares jumped 22.36% on continued strength after the announcement of insurance coverage of ANKTIVA across multiple states with the first commercial doses administered. Sasol Ltd. (NYSE:SSL) shares escalated 20.89% after the company announced that the court ruled in favor of the company and TotalEnergies SE (NYSE:TTE) Marketing. Also, it
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA
ImmunityBio, Inc. (NASDAQ:IBRX) shares are moving higher Thursday after the company announced insurance coverage of ANKTIVA across multiple states. The Details: ANKTIVA is a immunotherapy used to treat non-muscle invasive bladder cancer that was unresponsive to other specific treatments. The immunotherapy received FDA approval less than two months ago and the first doses of ANKTIVA have now been administered to patients located across the United States. “In addition to its unique mechanism of action, ANKTIVA can be readily administered by urologists in their own offices and clinics enabling more patients to receive it in familiar settings from their own providers,” said Richard Adco
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday. Shares of KB Home (NYSE:KBH) rose during Thursday's session as the company posted better-than-expected earnings and sales results for its second quarter on Tuesday. KB Home reported quarterly earnings of $2.15 per share, which beat the analyst consensus estimate of $1.78. Quarterly sales came in at $1.71 billion, which beat the analyst consensus estimate of $1.651 billion, according to data from Benzinga Pro. KB Home shares gained 4.2% to $70.91 on Thursday. Here are some other big stocks recording gains in today’s session. Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares climbed 16% to $6.36
Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancerANKTIVA launch initiates the next era of immunotherapy beyond checkpoint inhibitors that is based on cytokines and natural killer (NK) cellsANKTIVA's novel mechanism of action activates the body's immune system of natural killer and killer T cells to attack BCG resistant tumor cells and induce memory T cells resulting in a long duration of complete response exceeding 47 months1ANKTIVA reimbursement now covered by multiple healthcare plansUrologists treating eligible bladder cancer patients can learn mor
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume FULC PUT TRADE BULLISH 06/21/24 $7.00 $141.2K 50 1.4K GTHX PUT SWEEP BEARISH 07/19/24
ImmunityBio's (NYSE:IBRX) short percent of float has fallen 8.79% since its last report. The company recently reported that it has 55.14 million shares sold short, which is 35.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.23 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest